Selecta Biosciences, Inc. Operating CF/Net income

Operating CF/Net income of SELB for past 10 years: annual, quarterly and twelve month trailing (TTM) including Operating CF/Net income growth rates and interactive chart. Calculated as operating cash flow divided by net income to common shareholders. Also called income quality ratio. A ratio of greater than 1.0 usually indicates high-quality income, while a ratio of less than 1.0 indicates low-quality.


Highlights and Quick Summary

  • Operating CF/Net income for the quarter ending December 30, 2020 was 0.47 (a -106.96% decrease compared to previous quarter)
  • Year-over-year quarterly Operating CF/Net income decreased by -21.27%
  • Annual Operating CF/Net income for 2020 was -0.51 (a -154.49% decrease from previous year)
  • Annual Operating CF/Net income for 2019 was 0.93 (a 2.63% increase from previous year)
  • Annual Operating CF/Net income for 2018 was 0.91 (a 13.67% increase from previous year)
  • Twelve month Operating CF/Net income ending December 30, 2020 was -0.51 (a 18.26% increase compared to previous quarter)
  • Twelve month trailing Operating CF/Net income decreased by -174.25% year-over-year
Trailing Operating CF/Net income for the last four month:
30 Dec '20 29 Sep '20 29 Jun '20 30 Mar '20
-0.51 -0.43 0.67 0.68
Visit stockrow.com/SELB for comprehensive keystats, realtime prices, income statement, balance sheet, cash flow statement with 10 years of data, and state-of-the-art screener.

Historical Operating CF/Net income of Selecta Biosciences, Inc.

Most recent Operating CF/Net incomeof SELB including historical data for past 10 years.

Interactive Chart of Operating CF/Net income of Selecta Biosciences, Inc.

Selecta Biosciences, Inc. Operating CF/Net income for the past 10 Years (both Annual and Quarterly)

Year Q1 Q2 Q3 Q4 Fiscal Year
2020 0.47 -6.75 0.49 0.6 -0.51
2019 0.86 0.93 0.44 1.68 0.93
2018 0.87 1.0 0.9 0.84 0.91
2017 0.65 1.05 0.54 1.01 0.8
2016 -0.16 0.71 0.61 1.03 0.48
2015 0.0 0.74 1.09 0.69
2014 0.0 0.77

Business Profile of Selecta Biosciences, Inc.

Sector: Healthcare
Industry: Biotechnology
Selecta Biosciences, Inc., a clinical-stage biopharmaceutical company, researches and develops nanoparticle immunomodulatory drugs for the treatment and prevention of human diseases. The company's proprietary pipeline includes enzymes therapies, gene therapies, and other products and product candidates affected by undesired immune responses. Its lead product is SEL-212 that is in Phase III clinical trials for the treatment of chronic refractory gout, as well as develops a product candidate to treat IgA-mediated diseases, including IgA nephropathy, linear IgA bullous dermatitis, IgA pemphigus, and IgA vasculitis. The company also engages in the development of gene therapy product candidates that are in preclinical development, including MMA-101, a product candidate for the treatment methylmalonic academia; SEL-313, a product candidate to treat ornithine transcarbamylase deficiency; SEL-399, a product candidate to indicate appropriate dose of ImmTOR in humans to reduce the formation of antibodies to AAV capsids; and other products for the treatment of pompe disease, duchenne muscular dystrophy, and limb-girdle muscular dystrophy. In addition, it develops a product candidate to treat primary biliary cholangitis. The company has license and collaboration agreements with Swedish Orphan Biovitrum; Spark Therapeutics; Massachusetts Institute of Technology; Shenyang Sunshine Pharmaceutical Co., Ltd.; Asklepios BioPharmaceutical, Inc. Sarepta Therapeutics, Inc.; and IGAN Biosciences, Inc. Selecta Biosciences, Inc. was incorporated in 2007 and is headquartered in Watertown, Massachusetts.